Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30653314 | 0.92 | PTPN1 (0.58) | PTPN1 | |
| SCHEMBL29417900 | 0.92 | CASP3 (0.57) | PTPN1CTSSCASP3CTSBCTSK | |
| SCHEMBL24221105 | 0.90 | PTPN1 (0.60) | PTPN1KMT2A | |
| SCHEMBL29355030 | 0.90 | PTPN1 (0.60) | PTPN1KMT2A | |
| SCHEMBL8140875 | 0.88 | CASP3 (0.51) | CASP3KMT2A | |
| SCHEMBL31315496 | 0.88 | KMT2A (0.58) | CASP3KMT2A | |
| SCHEMBL29700028 | 0.87 | PTPN1 (0.56) | PTPN1CASP3CTSK | |
| SCHEMBL29990051 | 0.87 | PTPN1 (0.56) | PTPN1CASP3CTSK | |
| SCHEMBL14787476 | 0.87 | KMT2A (0.51) | CASP3KMT2A | |
| SCHEMBL30554761 | 0.87 | KMT2A (0.51) | CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116999408-A | Cathepsin B-sensitive fatty acid-doxorubicin prodrug, albumin nanoparticle thereof, preparation method and application | 沈阳药科大学 | 2023-11-07 | — | — | CN | claimed |
| CN-116789769-A | Preparation method of F3 polypeptide | 中奥生物医药技术(广东)有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-115747201-A | Preparation method of dynamic hydrogel | 华东理工大学 | 2023-03-07 | — | — | CN | claimed |
| EP-4682156-A1 | LINKER AND DRUG CONJUGATE USING SAME, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Shanghai Affinity Biopharmaceutical Co., Ltd. (CN) | 2026-01-21 | — | — | EP | disclosed |
| CN-118666946-A | Connector, coupling drug using same, antibody coupling drug and application of antibody coupling drug | 上海亲合力生物医药科技股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024188314-A1 | LINKER AND DRUG CONJUGATE USING SAME, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 上海亲合力生物医药科技股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| CN-116789769-B | Preparation method of F3 polypeptide | 中奥生物医药技术(广东)有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-112409458-B | Preparation method of carbetocin | 深圳翰宇药业股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117447336-A | Non-classical solid phase synthesis carrier and preparation method and application thereof | 瑞博(杭州)医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117304131-A | Alpha-carbonyl alkenyl ester compound, and preparation method and application thereof | 广州医科大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-116999408-A | Cathepsin B-sensitive fatty acid-doxorubicin prodrug, albumin nanoparticle thereof, preparation method and application | 沈阳药科大学 | 2023-11-07 | — | — | CN | disclosed |
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGXI NORMAL UNIVERSITY (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-13 | — | — | US | disclosed |
| CN-115746104-A | Preparation method of Bulevirtide | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115746102-A | Method for preparing Bulevirtide by combining solid phase with liquid phase | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115746103-A | Preparation method of Bulevirtide | 深圳市健翔生物制药有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115747201-A | Preparation method of dynamic hydrogel | 华东理工大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-113292430-B | Alpha-carbonyl alkenyl ester compound and preparation method and application thereof | 江西师范大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-114437233-A | Directional synthesis method of polypeptide dimer | 湖北健翔生物制药有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-112094324-B | Synthesis method of carbetocin | 宁波三生生物科技股份有限公司 | 2022-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ACSL1, ACSL4, WEE1 | PTPN1 4812/4885CTSS 1913/4885CASP3 3706/4885 |
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | QPCT, ANPEP, PEPD | PTPN1 443/4885CTSS 1548/4885CASP3 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.